Tratamiento farmacológico del hipertiroidismo actualmente
- Ana Carmen Seco Fernández
, - Javier Jaimes Cienfuegos,
- Javier Jaimes García
Resumen
El hipertiroidismo puede desenlazar en enfermedad cardiovascular fatal, así como repercutir sobre el sistema musculo-esquelético, con el subsecuente desarrollo de osteoporosis.
En este sentido es necesario actualizar el conocimiento farmacológico del personal de salud para el correcto tratamiento de la enfermedad tiroidea. Se recomienda iniciar con antitiroideos y observar la respuesta terapéutica al 18 meses con monitores bi o trimestrales, así como agregar como complemento otros fármacos como β-bloqueadores, colestiramina, perclorato, litio, selenio y corticosteroides, entendiendo su dosificación, indicación y efectos adversos.
Palabras clave
hipertiroidismo, tratamiento, Enfermedad de Graves
Biografía del autor/a
Ana Carmen Seco Fernández
Residente de tercer año de Otorrinolaringología y Cirugía de Cabeza y Cuello. Centro Médico ISSEMyM “Lic. Arturo Montiel Rojas”
Javier Jaimes Cienfuegos
Presidente del Comité de Bioética Universidad Autónoma del Estado de México
Javier Jaimes García
Docente de tiempo completo academia de farmacología Universidad Autónoma del Estado de México
Citas
- Werner SC. Classification of Thyroid Disease [Internet]. 1969 [cited 2023 Mar 28]. Available from: https://pubmed.ncbi.nlm.nih.gov/5814661/
- Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Vol. 14, Nature Reviews Endocrinology. Nature Publishing Group; 2018. p. 301–16.
- Duntas LH TBS. Classification of Thyroid Diseases. Luster M, DuntasLH Warftosky L The Thyroid and Its Diseases . 2018;(Springer.):87-99.
- Kravets I. Hyperthyroidism: Diagnosis and Treatment [Internet]. Vol. 93. 2016. Available from: www.aafp.org/afp
- Hoermann R, Midgley JEM, Larisch R, Dietrich JW. Relational stability in the expression of normality, variation, and control of thyroid function. Vol. 7, Frontiers in Endocrinology. Frontiers Media S.A.; 2016.
- Hoermann R, Midgley JE, Larisch R, Dietrich JW. Homeostatic Control of the Thyroid-Pituitary Axis: Perspectives for Diagnosis and Treatment. ,. Front Endocrinol (Lausanne). 2015;6, 177.
- Sheehan MT. Biochemical testing of the thyroid: TSH is the best and, oftentimes, only test needed - A review for primary care. Vol. 14, Clinical Medicine and Research. Marshfield Clinic; 2016. p. 83–92.
- Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016 Oct 1;26(10):1343–421.
- Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European thyroid association guideline for the management of graves’ hyperthyroidism. Vol. 7, European Thyroid Journal. S. Karger AG; 2018. p. 167–86.
- Winther KH, Bonnema SJ, Hegedüs L. Is selenium supplementation in autoimmune thyroid diseases justified? Vol. 24, Current Opinion in Endocrinology, Diabetes and Obesity. Lippincott Williams and Wilkins; 2017. p. 348–55.
- Abbara A, Clarke SA, Brewster R, Simonnard A, Eng PC, Phylactou M, et al. Pharmacodynamic Response to Anti-thyroid Drugs in Graves’ Hyperthyroidism. Front Endocrinol (Lausanne). 2020 May 12;11.
- Wang M, Yu Y. Therapeutic effects of combination regimens including methimazole on Graves hyperthyroidism: A network meta-analysis of randomized controlled trials. Vol. 26, Endocrine Practice. American Association of Clinical Endocrinologists; 2020. p. 675–87.
- Burch HB, Cooper DS. Management of graves disease a review. Vol. 314, JAMA - Journal of the American Medical Association. American Medical Association; 2015. p. 2544–54.
- Knight CL, Cooray SD, Kulkarni J, Borschmann M, Kotowicz M. Thyroidectomy for the treatment of Graves’ thyrotoxicosis in thioamide-induced agranulocytosis and sepsis. Endocrinol Diabetes Metab Case Rep. 2017 Sep 3;2017.
- Yang J, Zhu YJ, Zhong JJ, Zhang J, Weng WW, Liu ZF, et al. Characteristics of antithyroid drug-induced agranulocytosis in patients with hyperthyroidism: A retrospective analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years.
- Prakash I, Nylen ES, Sen S. Lithium as an Alternative Option in Graves Thyrotoxicosis. Case Rep Endocrinol. 2015;2015:1–4.
- Calissendorff J, Falhammar H. Lugol’s solution and other iodide preparations: perspectives and research directions in Graves’ disease. Endocrine. 2017 Dec 1;58(3):467–73.
- Bartalena L, Bogazzi F, Chiovato L, Hubalewska-Dydejczyk A, Links TP, Vanderpump M. 2018 European Thyroid Association (ETA) guidelines for the management of amiodarone-associated thyroid dysfunction. Vol. 7, European Thyroid Journal. S. Karger AG; 2018. p. 55–66.
- Suwansaksri N, Preechasuk L, Kunavisarut T. Nonthionamide Drugs for the Treatment of Hyperthyroidism: From Present to Future. Vol. 2018, International Journal of Endocrinology. Hindawi Limited; 2018.